
    
      A randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over,
      single-dose Phase IIa study to investigate the local and systemic effects of 3 different
      doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease (COPD)
    
  